![]() |
市場調查報告書
商品編碼
1755849
2032 年 γ-丁內酯市場預測:按等級、分銷管道、應用、最終用戶和地區進行的全球分析Gamma Butyrolactone Market Forecasts to 2032 - Global Analysis By Grade (Industrial Grade, Common Grade, Electronic Grade, and Pharmaceutical Grade), Distribution Channel, Application, End User and By Geography |
根據 Stratistics MRC 的數據,全球 γ-丁內酯市場預計在 2025 年達到 41 億美元,到 2032 年將達到 58.8 億美元,預測期內的複合年成長率為 5.3%。
γ-丁內酯 (GBL) 是一種無色、吸濕性液體有機化合物,常用作溶劑和化學中間體。它具有微弱的氣味,可溶於水和大多數有機溶劑。 GBL 在藥物、聚合物和電池化學品的生產中發揮重要作用。它也是N-甲基吡咯烷酮(NMP) 等其他化合物的前驅物。由於潛在的濫用風險,GBL 在許多國家/地區受到監管。
藥品需求不斷成長
GBL 是合成各種藥物(包括麻醉劑和鎮靜劑)的前驅物。製藥業對高純度溶劑的需求不斷成長,推動了市場擴張。此外,慢性病的流行導致處方量增加,進一步刺激了需求。對先進藥物製劑的監管支持也推動了 GBL 溶劑的採用。因此,製藥業仍然是 GBL 市場成長的主要驅動力。
原物料價格波動
丁內酯的生產依賴前體化學品,而前驅化學品的成本會因地緣政治緊張局勢和供應鏈中斷而波動。製造商難以維持價格穩定,進而影響利潤率。價格突然上漲會導致生產成本上升,使企業難以保持競爭力。儘管做出了這些努力,但價格波動仍然是市場成長的主要限制因素。
增加聚合物和樹脂的產量
GBL 廣泛用於聚氨酯合成,是汽車、建築和家具行業不可或缺的材料。這些產業的擴張推動了對高性能聚合物的需求,尤其是在新興國家。此外,聚合物技術的進步也推動了 GBL 基配方的採用。 GBL 在樹脂製造中的多功能性增強了其市場潛力。隨著各行各業對創新材料的追求,對 GBL 的需求預計將持續成長。
與替代溶劑的競爭
某些化學溶劑的監管限制正促使各行各業探索更環保的替代品。一些替代品以更低的成本提供類似的性能特徵,對GBL的市場地位構成挑戰。此外,溶劑技術的進步也推動了更高效替代溶劑的開發。投資永續溶劑解決方案的公司可能會逐漸放棄基於GBL的配方。因此,來自替代溶劑的競爭正成為市場擴張的主要威脅。
COVID-19的影響
新冠疫情對γ-丁內酯市場產生了多方面的影響。雖然供應鏈中斷影響了生產,但醫藥溶劑的需求卻激增。封鎖和限制措施導致對自動化生產流程的依賴增加,這對γ-丁內酯的採用起到了積極作用。疫情凸顯了醫療保健應用對高效能化學製劑的需求。疫情過後,預計對製藥和工業自動化的持續投資將維持市場成長。
預計工業級部分在預測期內將佔據最大佔有率。
由於工業級GBL應用廣泛,預計將在預測期內佔據最大的市場佔有率。工業級GBL廣泛應用於化學合成、清洗劑和電子製造。工業製程中對高純度溶劑的需求正在推動市場擴張。此外,電子和汽車產業的成長也推動了對工業GBL的需求。
預計預測期內溶劑部分將以最高的複合年成長率成長。
預計溶劑領域將在預測期內實現最高成長率。製藥、電子和農業化學品領域對高性能溶劑的需求不斷成長,推動了市場擴張。此外,溶劑技術的進步使GBL更有效率、用途更廣泛。對高純度溶劑的監管支持也進一步推動了市場成長。隨著各行各業尋求可靠的溶劑解決方案,GBL市場預計將迎來快速成長。
預計亞太地區將在預測期內佔據最大的市場佔有率。這是由於該地區製藥和化學工業的擴張推動了對γ-丁內酯的需求。政府支持工業自動化和化學品製造的措施也進一步推動了市場成長。亞太地區擁有主要的市場參與者,他們正在擴大產能。此外,電子和汽車行業對高性能溶劑的需求不斷成長也促進了市場擴張。
預計北美將在預測期內呈現最高的複合年成長率,因為該地區先進的醫療基礎設施和強力的法規結構支持GBL的採用。大型製藥和化學品製造商的存在正在加速對高純度溶劑的投資。此外,對高效工業流程的需求不斷成長也推動了市場擴張。對永續化學配方的日益關注也進一步推動了GBL的採用。
According to Stratistics MRC, the Global Gamma Butyrolactone Market is accounted for $4.10 billion in 2025 and is expected to reach $5.88 billion by 2032 growing at a CAGR of 5.3% during the forecast period. Gamma Butyrolactone (GBL) is a colorless, hygroscopic liquid organic compound commonly used as a solvent and chemical intermediate. It has a faint odor and is soluble in water and most organic solvents. GBL plays a crucial role in the production of pharmaceuticals, polymers, and battery chemicals. It is also a precursor to other compounds like N-Methyl-2-pyrrolidone (NMP). Due to its potential misuse, GBL is regulated in many countries.
Growing demand in pharmaceuticals
GBL serves as a precursor in the synthesis of various drugs, including anesthetics and sedatives. The increasing demand for high-purity solvents in pharmaceutical manufacturing is driving market expansion. Additionally, the rising prevalence of chronic diseases has led to higher prescription volumes, further boosting demand. Regulatory support for advanced pharmaceutical formulations is encouraging the adoption of GBL-based solvents. As a result, the pharmaceutical sector remains a key driver of GBL market growth.
Fluctuating raw material prices
GBL production relies on precursor chemicals, whose costs fluctuate due to geopolitical tensions and supply chain disruptions. Manufacturers face difficulties in maintaining stable pricing, impacting profit margins. Sudden price hikes can lead to increased production costs, making it harder for companies to remain competitive. Despite these efforts, price instability remains a significant restraint for market growth.
Increased production of polymers and resins
GBL is widely used in the synthesis of polyurethanes, which are essential in automotive, construction, and furniture industries. The expansion of these sectors, particularly in emerging economies, is driving the need for high-performance polymers. Additionally, advancements in polymer technology are increasing the adoption of GBL-based formulations. The versatility of GBL in resin production enhances its market potential. As industries seek innovative materials, the demand for GBL is expected to rise.
Competition from alternative solvents
Regulatory restrictions on certain chemical solvents are prompting industries to explore greener alternatives. Some substitutes offer similar performance characteristics at a reduced cost, challenging GBL's market position. Additionally, advancements in solvent technology are leading to the development of more efficient alternatives. Companies investing in sustainable solvent solutions may shift away from GBL-based formulations. As a result, competition from alternative solvents remains a key threat to market expansion.
Covid-19 Impact
The COVID-19 pandemic had a mixed impact on the Gamma Butyrolactone market. While disruptions in supply chains affected production, the demand for pharmaceutical solvents surged. Lockdowns and restrictions led to increased reliance on automated manufacturing processes, benefiting GBL adoption. The pandemic highlighted the need for efficient chemical formulations in healthcare applications. Post-pandemic, continued investment in pharmaceutical and industrial automation is expected to sustain market growth.
The industrial grade segment is expected to be the largest during the forecast period
The industrial grade segment is expected to account for the largest market share during the forecast period, due to its extensive applications. Industrial-grade GBL is widely used in chemical synthesis, cleaning agents, and electronic manufacturing. The demand for high-purity solvents in industrial processes is driving market expansion. Additionally, the growth of the electronics and automotive sectors is boosting the need for industrial-grade GBL.
The solvent segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the solvent segment is predicted to witness the highest growth rate, due to The increasing demand for high-performance solvents in pharmaceuticals, electronics, and agrochemicals is fuelling market expansion. Additionally, advancements in solvent technology are enhancing GBL's efficiency and versatility. Regulatory support for high-purity solvents is further boosting market growth. As industries seek reliable solvent solutions, the GBL market is expected to experience rapid growth.
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to the region's expanding pharmaceutical and chemical industries are driving demand for Gamma Butyrolactone. Government initiatives supporting industrial automation and chemical manufacturing are further boosting market growth. The presence of key market players in Asia Pacific enhances production capabilities. Additionally, the rising demand for high-performance solvents in electronics and automotive sectors is contributing to expansion.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to the region's advanced healthcare infrastructure and strong regulatory framework support GBL adoption. The presence of leading pharmaceutical and chemical manufacturers is accelerating investment in high-purity solvents. Additionally, rising demand for efficient industrial processes is driving market expansion. The growing focus on sustainable chemical formulations is further boosting GBL adoption.
Key players in the market
Some of the key players profiled in the Gamma Butyrolactone Market include BASF SE, Mitsubishi Chemical Group Corporation, Ashland, Dairen Chemical Corporation (DCC), Sipchem Company, Balaji Amines, LyondellBasell Industries, Hefei TNJ Chemical Industry Co., Ltd., Zhejiang Realsun Chemical Co., Ltd., Chang Chun Group, Boai NKY Pharmaceuticals Ltd., Biosynth, CDH Fine Chemicals, Dongao Chemical, and Tokyo Chemical Industry Co., Ltd. (TCI).
In May 2025, BASF Coatings expands business with biomass-balanced products, BASF Coatings is consistently pursuing its strategic roadmap for sustainable development and is further expanding its business with biomass-balanced products. Following successful launches in Europe and Asia, the first products for the automotive refinish coatings market will now also be introduced in North America this year.
In May 2025, Mitsubishi Tanabe Pharma Corporation announced that Radicava(R) (generic name: edaravone, Japanese product name: RADICUT(R) inj.30mg) for an intravenous treatment for amyotrophic lateral sclerosis (ALS) has been launched in Australia on May 1 by a local licensee, Teva Pharma Australia Pty Ltd.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.